Competition Prospecting Safety 
Infuse Medical
MAY 14, 2024
Continuous learning and skill development are essential for maintaining a competitive edge in the dynamic field of medical device sales. Regulatory Considerations Medical device marketing using VR must adhere to regulatory guidelines and standards to ensure patient safety and compliance.
Pharmaceutical Representative Training
OCTOBER 9, 2024
Introduction Every sales professional has experienced deals collapsing at the last minute due to objections from prospects. In the competitive world of pharmaceutical sales, effectively handling customer objections is crucial for success. There are times when your prospect will have multiple objections at once.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 22, 2023
Dr. Jerry Mendell, MD, professor of paediatrics and neurology at the Ohio State University College of Medicine, is optimistic for its approval and says the drug has a good safety profile. However, before the drug can receive an approval, Santhera will have to overcome doubts about vamorolone’s safety. compared to 38.5% on placebo.
Pharmaceutical Technology
JUNE 20, 2023
This comes after an independent data monitoring committee confirmed the safety and tolerability profile of ARGX-117 was consistent with results from an earlier Phase I study. In addition to assessing the safety and efficacy of ARGX-117, it will populate a PK/PD model to inform Phase III study dose selection.
Pharmaceutical Technology
AUGUST 5, 2022
With respect to its safety profile, Cimerli had more than 3% fewer adverse events (AEs) than Lucentis; however, there were no clinically relevant differences for safety. Thus, the biosimilar presented a similar efficacy to the reference product. Cimerli’s biosimilar status is appealing to providers and patients alike in the US.
Pharmaceutical Technology
MAY 31, 2023
The Danish CRISPR biotech SNIPR BIOME has released the first glimpse at the safety profile for SNIPR001, a gene therapy intended to target antibiotic resistance. Interim clinical results from a Phase I trial have demonstrated SNIPR001’s safety in healthy volunteers. SNIPR001 consists of four CRISPR-edited phages targeting E.Coli.
Healthcare Success
JULY 5, 2022
Not only are doctors and decision-makers difficult to reach—and even more difficult to persuade—you have to contend with a ton of competition. Here are two ways to define your doctor audience: Target your best prospects Enhance your database to target more precisely. Target Your Best Prospects. More data is always better.
Expert insights. Personalized for you.
130 
Let's personalize your content